Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | HTR1B | P28222 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | HTR7 | P34969 | 2/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL407234 | 0.86 | SLC6A4 (0.42) | ALDH1A1SLC6A2SLC6A4SLC6A3KDM4E | |
| SCHEMBL405209 | 0.81 | SLC6A2 (0.54) | ALDH1A1SLC6A2SLC6A4SLC6A3KDM4E | |
| SCHEMBL406400 | 0.69 | CYP19A1 (0.52) | ALDH1A1SLC6A2SLC6A4SLC6A3KDM4E | |
| SCHEMBL407204 | 0.67 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL406421 | 0.66 | SLC6A4 (0.48) | ALDH1A1SLC6A2SLC6A4SLC6A3KDM4E | |
| SCHEMBL407502 | 0.66 | SLC6A2 (0.43) | ALDH1A1SLC6A2SLC6A4SLC6A3LTB4R | |
| SCHEMBL23980607 | 0.66 | KDM4E (0.53) | ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL17023206 | 0.65 | KDM4E (0.38) | ALDH1A1SLC6A2SLC6A4SLC6A3KDM4E | |
| SCHEMBL407149 | 0.65 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL405303 | 0.65 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101642-B2 | 3-substituted propanamine compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2012-01-24 | — | — | US | claimed |
| EP-2285787-A2 | 3-SUBSTITUTED PROPANAMINE COMPOUNDS | SK Holdings Co., Ltd. (KR) | 2011-02-23 | — | — | EP | claimed |
| EP-2285787-B1 | 3-SUBSTITUTED PROPANAMINE COMPOUNDS | SK BIOPHARMACEUTICALS CO LTD (KR) | 2015-08-26 | — | — | EP | disclosed |
| US-8404730-B2 | 3-substituted propanamine compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2013-03-26 | — | — | US | disclosed |
| US-20120046312-A1 | 3-SUBSTITUTED PROPANAMINE COMPOUNDS | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2012-02-23 | — | — | US | disclosed |
| US-8101642-B2 | 3-substituted propanamine compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2012-01-24 | — | — | US | disclosed |
| EP-2285787-A2 | 3-SUBSTITUTED PROPANAMINE COMPOUNDS | SK Holdings Co., Ltd. (KR) | 2011-02-23 | — | — | EP | disclosed |
| US-20100311789-A1 | 3-Substituted Propanamine Compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2010-12-09 | — | — | US | disclosed |
| WO-2009148290-A2 | 3-SUBSTITUTED PROPANAMINE COMPOUNDS | SK HOLDINGS CO., LTD. (KR) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046312-A1 | 3-SUBSTITUTED PROPANAMINE COMPOUNDS | ADRB3, PNMT, OPRK1 | ALDH1A1 177/4885SLC6A2 31/4885SLC6A4 47/4885 |
| US-20100311789-A1 | 3-Substituted Propanamine Compounds | ADRB3, PNMT, OPRK1 | ALDH1A1 177/4885SLC6A2 31/4885SLC6A4 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.